LAG3 and neoplasm: However, there is currently an increasing diversity in treatment options, with new ICIs that enhance cancer treatment efficacy across a broad range of tumor types, such as anti-LAG-3 (Relatlimab) [78], anti-TIGIT (Tiragolumab) [79] and anti-TIM-3 mabs [80].